Hunan Hansen Pharmaceutical Co., Ltd. (002412.SZ)

Hunan Hansen Pharmaceutical Co., Ltd. (002412.SZ) — VMCI valuation read

Hunan Hansen Pharmaceutical Co., Ltd. (002412.SZ) carries a VMCI composite of 58/100, 8 points above the Healthcare sector median of 50. Among mid-cap names, that gap places 002412.SZ in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 002412.SZ insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 002412.SZ trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.2x leaves covenant headroom, the line to track on Hunan Hansen Pharmaceutical Co., Ltd.'s next 10-Q.

002412.SZ rose 1.3% over the trailing 7 days, with a +3.1% read on a 30-day basis.